Which Healthcare ETF Is the Better Buy: Vanguard's VHT or iShares' IXJ?

Vanguard Health Care ETF (VHT) is positioned as the cheaper, more diversified option versus iShares Global Healthcare ETF (IXJ), charging 0.09% vs 0.38% in annual fees (about $9 vs $38 per $10,000 position). VHT also shows slightly higher dividend yield at 1.55% vs 1.44%, while delivering a 1-year total return of 31.21% vs 23.92% for IXJ. With broader exposure (417 holdings vs 110), the article argues VHT is the better default for long-term healthcare exposure, with IXJ mainly appealing for investors specifically seeking non-U.S. names.

Analysis

This is less a sector call than a fee-and-flow trade. In a world where both funds are dominated by the same mega-cap U.S. names, the lower-cost wrapper should gradually siphon marginal allocator dollars from the higher-fee one, especially in model portfolios and advisor platforms that compete on tracking error and expense ratio. That creates a quiet tailwind for VHT relative to IXJ over the next 1-6 months, but it is unlikely to move the underlying mega-caps in a meaningful way unless flows become unusually large.

The more interesting second-order effect is breadth. VHT’s deeper exposure to smaller domestic biotech and med-tech names means incremental inflows have a better chance of trickling into less-owned parts of healthcare, which can support valuations at the margin and compress spreads in names with better balance sheets and cleaner growth. IXJ’s thinner non-U.S. sleeve also means investors think they are getting diversification they are not really buying, so any risk-off move that favors “quality U.S. defensives” over globally exposed health care could keep VHT on the better side of the relative return line.

Catalyst-wise, this is a slow-burn story, not a binary event. The key reversal risk is if international pharma outperforms on currency, policy, or litigation dispersion, which would make IXJ’s regional diversification matter more than the fee gap over a 6-18 month horizon. Near term, the thesis is falsified if IXJ continues to match or beat VHT despite the cost handicap, implying that non-U.S. healthcare exposure is becoming the scarce factor investors actually want rather than the cheaper implementation vehicle.

Bottom line: the article is mildly supportive of U.S. healthcare and specifically of the lower-cost wrapper, but the signal is too modest for a broad sector overweight by itself. The best risk/reward is a relative-value expression that isolates wrapper preference rather than a directional bet on the sector.

Key Decisions for Investors

• Long VHT / short IXJ as a 3-6 month relative-value pair trade. Thesis: the fee differential and broader U.S. breadth should attract incremental assets; target modest outperformance of VHT, with the trade failing if IXJ closes the return gap on a rolling 3-month basis.
• If you want the cleaner sector beta, prefer XLV or VHT over IXJ for new healthcare allocations over the next 1-3 months. The edge is not explosive, but fee drag compounds and should matter in low-volatility defensive sleeves.
• Use IXJ as a hedge only if you specifically want non-U.S. pharma diversification; otherwise avoid initiating new IXJ exposure after a relative-strength pop. Entry discipline matters because the expected alpha is mostly structural, not event-driven.
• Watch LLY, JNJ, and ABBV for passive-flow support rather than fundamental re-rating. Any sustained underperformance versus the sector after healthcare inflows would argue the market is not rewarding ETF ownership, weakening the VHT-support thesis.